Navigation Links
Charleston Laboratories and Daiichi Sankyo Announce Collaboration to Develop and Commercialize Novel, Fixed-Dose Combination Hydrocodone Products for Pain and Opioid-Induced Nausea and Vomiting (OINV) in the US
Date:8/7/2014

8 in the United States. Charleston Laboratories will be responsible for manufacturing activities for CL-108 and will receive the right to co-promote this and other hydrocodone products in the United States.

Under the terms of the agreement, which is pending HSR clearance, Charleston Laboratories will receive $200 million split evenly between an upfront cash payment and a near-term milestone, and up to an additional $450 million in milestone payments connected to FDA filing and approval of its novel fixed-dose hydrocodone products in the United States.  In addition, Charleston Laboratories will receive escalating, tiered, double-digit share of the gross operating margin from the products, and will be responsible for supplying all product.  

"We are proud to partner with Charleston Labs on this exciting and unique fixed-dose combination tablet, which will seek to simultaneously address severe pain and opioid-related nausea and vomiting to benefit patients," said Dr. Mahmoud Ghazzi, Global Head of Development and Executive Vice President at Daiichi Sankyo.

"CL-108 represents an opportunity at the intersection of innovation and patient need," said Ken Keller, President, U.S. Commercial of Daiichi Sankyo, Inc. "Daiichi Sankyo has proven success in the U.S. primary care arena, a key market for pain management, and we look forward to the potential of CL-108."

"From our inception, it has been our goal to identify an industry-leading partner that is patient-focused, with a shared appreciation for the importance of educating healthcare providers on the significant issue of Opioid-Induced Nausea and Vomiting," said Ryan Baker, Founder and Chief Operating Officer of Charleston Laboratories. "Daiichi Sankyo has successfully commercialized several medicines in '/>"/>

SOURCE Charleston Laboratories, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Charleston Laboratories, Inc. beginnt mit klinischer Phase 3-Studie für CL-108
2. Charleston Laboratories, Inc. Begins Enrollment for CL-108 Phase 3 Clinical Trial
3. FDA Grants Charleston Laboratories, Inc. Request for Pre-IND Meeting on New Migraine Treatment
4. Charleston Laboratories, Inc. Announces Successful Completion of Pre-IND Meeting on New Migraine Treatment CL-H1T
5. Strong Efficacy Data Prompt Charleston Laboratories to Halt Phase 3 Study of CL-108 in Patients with Moderate to Severe Acute Pain
6. CHPA to Address Anti-Meth Policy at AP Lookahead Event Today in Charleston
7. CHPA Addresses Anti-Meth Policy at AP Lookahead Event Today in Charleston
8. Daiichi Sankyo and Charleston Laboratories Announce Collaboration to Develop and Commercialize Novel, Fixed-Dose Combination Hydrocodone Products for Pain and Opioid-Induced Nausea and Vomiting (OINV) in the US
9. Ameritox Files Amended Complaint Against Millennium Laboratories For Injunctive Relief, Declaratory Relief and Damages
10. Millennium Laboratories Sponsors Educational Programs in Support of Safe Prescribing Practices at Regional Pain Society Conferences
11. Grant & Eisenhofer Represents Lead Whistleblower in Historic $1.6 Billion Settlement with Abbott Laboratories Over Off-Label Marketing of Antiepileptic Medication Depakote
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Tenn. , Sept. 16, 2014 A ... investigators has found the chemotherapy dose threshold below ... normal sperm production. The study appears in September 17 ... By clarifying which patients are at highest risk ... findings to eventually increase use of pre-treatment fertility preservation ...
(Date:9/16/2014)... -- Chindex International, Inc. ("Chindex" or the "Company") (Nasdaq: ... meeting of stockholders held today, the Company,s stockholders adopted ... and among the Company, Healthy Harmony Holdings, L.P. ("Parent"), ... an affiliate of TPG, Shanghai Fosun Pharmaceutical (Group) Co., ... CEO of the Company. The Merger Agreement ...
(Date:9/16/2014)... , Sept. 16, 2014 Research and Markets ... Vaccines Market 2014-2018" report to their offering. ... immunity of animals. Animal vaccines are generally prepared from weakened ... in their healthy state. Some of the animal vaccines are ... as protein subunits or toxic components. These ...
Breaking Medicine Technology:Improved risk identification will aid fertility preservation in young male cancer patients 2Improved risk identification will aid fertility preservation in young male cancer patients 3Improved risk identification will aid fertility preservation in young male cancer patients 4Chindex Stockholders Approve Merger 2Chindex Stockholders Approve Merger 3Global Animal Vaccines Market 2014-2018: Key Vendors are Bayer, Elanco, Merck, Novartis, Sanofi and Zoetis 2Global Animal Vaccines Market 2014-2018: Key Vendors are Bayer, Elanco, Merck, Novartis, Sanofi and Zoetis 3
... BioStorage Technologies, Inc., a worldwide provider of long- and ... logistics, will expand its European operations with the opening ... full-service biorepository in Frankfurt, Germany. , BioStorage Technologies, expanded ... plan to accommodate a rapidly growing list of customers ...
... Oct. 21 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHMD) ... bavituximab in combination with docetaxel in patients with advanced breast ... planned treatment cycles in the Phase II study showed that ... the trial achieved an objective tumor response according to RECIST ...
Cached Medicine Technology:BioStorage Technologies, Inc., Accelerates European Expansion with Opening of New German Facility 2Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer 2Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer 3Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer 4
(Date:9/17/2014)... 17, 2014 ICS Learning Group, Inc. ... Excellence in Training for the Best Use of Games ... on an online operational safety training module that ICS ... operation. Using an approach that combined realistic 3D ... that was similar to a video game, including competition ...
(Date:9/17/2014)... 2014 Health.Verticalize, a healthcare marketing company ... health insurance options in the 2014 open enrollment period, ... Moving forward Health Network will be using ... has intentionally remained out of the spotlight for the ... single website to its present position with dozens of ...
(Date:9/16/2014)... Recently, BamboofloorChina.com, the popular online supplier ... of strand woven bamboo floors to its ... big promotion for the new items; the current discount ... is a great shopping season. Therefore, BamboofloorChina.com spares no ... new customers. All practical items offered by BamboofloorChina.com are ...
(Date:9/16/2014)... UK report a poorer experience of care during pregnancy ... their care, suggests a new study published today (17 ... and Gynaecology ( BJOG ). , Differences in ... in many areas and have provided the focus for ... inequalities. , The Oxford University study, funded by the ...
(Date:9/16/2014)... Holganix, an elite member of the Inc ... the country, produces an organic Bionutritional product that promotes ... decreasing disease and insect damage though significant root and ... hold its third annual Bionutritional Summit at the Seelbach ... 1:00 P.M. through 6:00 P.M., the day before the ...
Breaking Medicine News(10 mins):Health News:ICS Learning Group Wins Gold in the 2014 Brandon Hall Excellence Competition for Best Use of Games and Simulations for Learning 2Health News:Health.Verticalize Rebrands as Health Network After Growing to 15 Million Users in Less Than One Year 2Health News:Health.Verticalize Rebrands as Health Network After Growing to 15 Million Users in Less Than One Year 3Health News:BamboofloorChina.com Announces Its Promotion For Strand Woven Bamboo Floors 2Health News:A greater focus on socially disadvantaged women is needed to improve maternity care in England 2Health News:Holganix Holds 3rd Annual Bionutrional Summit in Louisville, Kentucky 2
... Medical School in the South West of England have ... out of hours services in primary care are reluctant ... and carried out telephone interviews with 27 patients who ... practice cover in the evenings and weekends in England. ...
... WANTAGH, N.Y., Nov. 29 As family members age, ... performing daily,tasks, such as cooking and laundry. Some need ... professional medical care, and most,want to stay in the ... how to keep their parents safe, healthy and cared ...
... U.S. is caused by a form of bacteria, the ... It typically begins with a bulls-eye skin rash, accompanied ... If diagnosed early, Lyme can be treated successfully within ... Nearly 60 percent of patients who do not receive ...
... Appointed Worldwide Managing Partners, NEW YORK, Nov. ... the,largest fully integrated, global health marketing and communications ... the credit going to,its unique leadership team whose ... leadership, effective immediately, Doug Burcin and Donna,Murphy, Partners, ...
... -- There are estimated to be ... diagnosed with chronic Immune Thrombocytopenic Purpura (ITP), an ... platelets in their blood -- causing bruises, nosebleeds ... of an international multicenter clinical research study led ...
... Receives Failing Grades on Key Benchmarks, WASHINGTON, ... its first-ever state-specific Report,Card on Lung Cancer. The ... lethal disease by the state of Massachusetts. LCA-MA ... Lung cancer is the number one cause of ...
Cached Medicine News:Health News:Out of hours doctors reluctant to do home visits, say patients 2Health News:Finding Ways for Seniors to Stay Safe, Healthy... and Home 2Health News:Finding Ways for Seniors to Stay Safe, Healthy... and Home 3Health News:Antibody responses in patients with Lyme arthritis 2Health News:Antibody responses in patients with Lyme arthritis 3Health News:World's Largest Fully Integrated, Global Health Marketing and Communications Group Appoints Global Leadership Team 2Health News:World's Largest Fully Integrated, Global Health Marketing and Communications Group Appoints Global Leadership Team 3Health News:Eltrombopag studied in Idiopathic Thrombocytopenic Purpura 2Health News:Lung Cancer Alliance-Massachusetts Issues Inaugural State-Specific Report Card on Lung Cancer 2
... The Accutest H. pylori WB ... for the qualitative detection of ... pylori in human whole blood. ... as an aid in the ...
... Rapid 5 minutes immunoassay, based on ... a monoclonal antibody, for the qualitative ... human stool. The Premier Platinum HpSA, ... after extensive evaluation, was accepted as ...
Unitary one step immuno-chromatographic assay for the qualitative detection of infectious mononucleosis heterophile antibodies in human serum, plasma or whole blood....
The NOW® Flu B test is the most frequently adopted rapid flu test on the market today. Testing could not be easier and the results are available in 15 minutes. Now you can focus on the results an...
Medicine Products: